ClinicalTrials.gg
RecruitingNCT07077486Updated Jan 27, 2026

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

A Phase 4 interventional study of Methylprednisolone (Corticosteroid) and Immunosuppressant other than CYC in Lupus or SLE, Interstitial Lung Disease and Systemic Lupus Erythematosus, sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Tongji Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
70th of 245
100 · median 36
Started
2025
with 61 others
Phase 4
16 of 266
6 open now
Primary completion
2026-10
later than 61 of 190 live
Registered
105th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 70th largest by planned enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 16 in phase 4, reaches primary completion later than 61 of the 190 other live ones, and was the 105th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.

Read the detailed description

Pulmonary abnormalities are present in up to 60% of patients with SLE, and up to 10% of the patients will develop clinical interstitial lung disease (ILD). Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus. The study also explores disease mechanisms in lungs and serum immunological interaction, to identify potential biomarkers for diagnosis, prognosis, and response to treatment of lupus-ILD.

03

Conditions studied

  • Lupus or SLE
  • Interstitial Lung Disease
  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus;
  • Male or non-pregnant female aged ≥ 18 years;
  • Diagnosis by high-resolution lung CT (HRCT) is clearly consistent with interstitial lung disease (ILD);
  • /FVC%≥60% and diffusion function DLCO (measured value/estimated value) ≥40%;
  • Patients voluntarily participate in this trial, have good compliance, and have the ability to understand and sign before the study.

Exclusion criteria

Exclusion Criteria:

  • and/or aspartate aminotransferase (ALT/AST) > 5 times the ;
  • severe chronic kidney disease (stage IV) or need for dialysis (estimated (eGFR) \< 30ml/min/1.73m2);
  • \< 80 g/L;
  • WBC \< 2.0×10\^9;
  • \< 50×10\^9;
  • Is pregnant or breastfeeding;
  • Expected transfer to another hospital in a non-study site within 4 weeks (possibility of loss to follow-up);
  • does not exceed 24 weeks;
  • Have a history of severe allergies;
  • Patients with other serious lung diseases or other serious abnormalities in the lungs;
  • Are using antitumor drugs, other or immunomodulatory therapies;
  • Significant pulmonary hypertension;
  • Previous clinical or echocardiographic evidence of significant right heart failure;

    1. Right heart catheterization showing cardiac index ≤ 2 L/min/m2;
    2. Pulmonary hypertension requiring treatment with epoprostenol/traprostacyclin.
  • Patients with severe cardiovascular disease:

    1. myocardial infarction within 6 months;
    2. Unstable angina within 6 months.
  • Risk of bleeding, any of the criteria listed below:

    1. known genetic predisposition to bleeding;
    2. Patients who require the following treatments:

    i. Fibrinolytic therapy, full-dose therapeutic anticoagulation (e.g., vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin); ii. High-dose antiplatelet therapy. [Note: Prophylactic low-dose heparin or heparin flush solution (e.g., enoxaparin, 4000 I.U. S.C. per day) required for maintenance of indwelling intravenous access devices is not prohibited.) and prophylactic antiplatelet therapy (e.g., acetylsalicylic acid up to 325 mg/day, or clopidogrel at a dose of 75 mg/day, or other antiplatelet therapy at the same dose).

  • History of hemorrhagic central nervous system (CNS) events within 12 months;
  • Any of the following conditions within a period of 3 months:

    1. hemoptysis or hematuria;
    2. Active gastrointestinal bleeding or gastrointestinal ulcers;
  • Have previously undergone hematopoietic stem cell transplantation (), or plan to receive HSCT in the following year, or plan to undergo major surgery.
  • Women who are pregnant, breastfeeding or planning to become pregnant during the test;
  • 28 days before administration or 3 months after administration, women of childbearing age are unwilling or unable to use highly effective methods;
  • According to the investigator's point of view, the patient has alcohol or drug abuse;
  • History of dysphagia or any gastrointestinal disease that affects drug
  • Patients with to the use of tatacept;
  • Subjects deemed unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    glucocorticoids and/or immunosuppressants other than CYC+ treatment with the Telitacicept group

    Telitacicept 160mg sc qw, plus standard of care therapy including glucocorticoids and/or immunosuppressants other than CYC sush as , tacrolimus, Sirolimus, cyclosporine, leflunomide, azathioprine, motecophenol ester, hydroxychloroquine, tripterine, methotrexate and sulazazopyridine. None of the cyclophosphamide usage was included in the group.

    Drug: Methylprednisolone (Corticosteroid) · Drug: Immunosuppressant other than CYC · Drug: Telitacicept Freeze-dried powder Injection 80mg

  • Active comparator
    glucocorticoids plus CYC and/or other immunosuppressants

    All patient in this group were administered with cyclophosphamide. The other immunosuppressants in this group include , tacrolimus, Sirolimus, cyclosporine, leflunomide, azathioprine, motecophenol ester, hydroxychloroquine, tripterine, methotrexate and sulazazopyridine. None of the biological agents like belimumab (Benlysta), anifrolumab (Saphnelo), telitacicept (TaiAi), tocilizumab (Actemra) and rituximab (Rituxan) was included in this group.

    Drug: Methylprednisolone (Corticosteroid) · Drug: Immunosuppressant other than CYC · Drug: Cyclophosphamide (CYC)

Interventions

  • DrugMethylprednisoloneStudies of MethylprednisoloneMethylprednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In addition to conventional treatment (methyl-40mg or less /d), the treatment group also received hydroxychloroquine (100mg-200mg each time twice a day), and thalidomide (50mg-100mg each time once a day) could be added as appropriate.

    Also known as: Methyl

  • DrugImmunosuppressant other than CYC

    The control group only received conventional treatment (methyl 40 mg/d or less), and other traditional immunosuppressants (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, motecophenol ester, hydroxychloroquine, tripterine, methotrexate and sulazazopyridine, etc.). No more than 3 types of immunosuppressant should be added during the whole treatment period, and the dose should not exceed 30% from the baseline period)

  • DrugTelitacicept Freeze-dried powder Injection 80mg

    Telitacicept is a TACI-Fc fusion protein, a type of drug used to treat autoimmune diseases. It works by targeting two key proteins, BLyS and APRIL, which are involved in the development and function of B cells, a type of white blood cell. By blocking these proteins, telitacicept can help to reduce B cell activity and suppress the immune system's overactivity in autoimmune diseases. Subcutaneous injection dose ranges from 80mg once a week to 160mg once a week.

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide iv injection is used for severe complications of systemic lupus erythematosus 400mg twice a week

06

What researchers measure

Primary outcomes

  1. Correlation between change from baseline at week 52 in forced vital capacity (FVC) [percentage (%) predicted]

    Pulmonary function measurement (FEV1/FVC% % post-treatment difference during baseline)

    Time frame: At baseline and at week 24, 52

Secondary outcomes

  1. Correlation between change from baseline at week 52 in diffusing capacity for carbon monoxide (DLco) [percentage (%) predicted]

    Diffuse function DLco measurement (% post-treatment difference at baseline)

    Time frame: At baseline and at week 24, 52

  2. Anti-double-stranded DNA antibody conversion ratio

    Anti-double-stranded DNA antibody conversion ratio

    Time frame: At baseline and at week 12, 24, and 52

  3. Complement C3 and C4 levels return to normal ratios

    Complement C3 and C4 levels return to normal ratios

    Time frame: At baseline and at week 12, 24, and 52

  4. Six minutes walking distance

    The 6-minute walk test (6MWT) is a simple, submaximal exercise test commonly used to assess functional capacity in individuals with interstitial lung disease (ILD). It measures the distance a person can walk in six minutes, and this distance (6MWD) can be correlated with disease severity and prognosis.

    Time frame: At baseline and at week 12, 24, and 52

  5. Changes from baseline in cumulative corticosteroid dose at week 52

    Baseline dose was defined as the average corticosteroid dose (prednisone equivalent for all oral, IV, subcutaneous \[SC\], or intramuscular \[IM\] administrations) over the 7 days prior to, but not including, day 0; this was used to model the normalized cumulative baseline dose over 52 weeks. Actual cumulative corticosteroid dose (prednisone equivalent for all oral, IV, SC, or IM administrations) over 52 weeks was calculated

    Time frame: At baseline and at week 52

  6. Krebs von den Lungen-6

    Krebs von den Lungen-6 (KL-6), is a biomarker primarily associated with interstitial lung disease (ILD). It's a high-molecular-weight mucin-like glycoprotein produced by type II alveolar pneumocytes. Elevated KL-6 levels in the blood can indicate the presence, severity, and progression of ILD.

    Time frame: At baseline and at week 12, 24, and 52

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2026, 14 months after the start.

Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2023
First posted
Jul 22, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Oct 25, 2026
CompletionEst.
Mar 25, 2027
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07077486
Lead sponsor
Tongji Hospital
Collaborators
Wuhan Central Hospital, Wuhan Hospital of Traditional Chinese Medicine, Rongchang Biopharmaceutical, Johns Hopkins Bloomberg School of Public Health
Responsible party
YIKAI YU (the Deputy Chief Physician, Tongji Hospital) — Principal investigator
First posted
Jul 22, 2025
Start date
Aug 25, 2025
Primary completion
Oct 25, 2026 (estimated)
Completion
Mar 25, 2027 (estimated)
Last update
Jan 27, 2026

Study contacts

YIKAI Dr. YU, M.D
Contact
yuyikai@163.com
+86-15671678920

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion